Get ready for the magic mushroom…
Even a decade ago, psychedelic drugs were limited to a fringe of mystics and experiential adventurers, just as they had been in Western societies for most of modernity. Today they’re approaching mainstream acceptance. It’s been a dizzying turnabout. Helping to drive the shift is a growing scientific literature that ratifies what the mystics have long said: These compounds can heal… as a result, what once was a scene is now an industry. There are more than 50 publicly traded psychedelic companies listed on US exchanges alone, and startups, like fruiting bodies, are sprouting all the time… at such a pace, an opinion piece in the journal JAMA Psychiatry pointed out, the industry “may even outpace the legal US cannabis market.”
“The psychedelic treatment model is not well-suited to the medical infrastructure that we have,” [Stanford collaborator] Heifets, a doctor and neuroscientist, says. Therapists are often in short supply in the US, and their care can be difficult if not impossible to receive reimbursement for from insurers… As for Numinus, it does need to make money. Like Compass, it has an intellectual-property strategy, albeit one that tries harder not to offend the ethics of the psychedelic underground. “We think psilocybin will probably just be generic, and clients will have the choice of what product they would like to use,” Nyquvest says. “And we believe that there’s going to be a number of people that would prefer a natural event.” [In 2021], Numinus filed for a US patent on techniques to rapidly produce natural psychoactive fungi species, and it has also filed a similar patent internationally.
Original Article (Bloomberg):
Get ready for the magic mushroom pill
Artwork Fair Use: Evlyshroom